Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis: a case series | Zendy

Droitcourt C. | Zendy; Adamski H. | Zendy; Polat A. | Zendy; Polard E. | Zendy; Kerjouan M. | Zendy; Arnouat B. | Zendy; Le Garrec M. | Zendy; Oger E. | Zendy; Dupuy A. | Zendy; Jouneau S. | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Pirfenidone photosensitization in patients with idiopathic pulmonary fibrosis: a case series

Author(s) -

Droitcourt C.,

Adamski H.,

Polat A.,

Polard E.,

Kerjouan M.,

Arnouat B.,

Le Garrec M.,

Oger E.,

Dupuy A.,

Jouneau S.

Publication year - 2018

Publication title -

british journal of dermatology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.304

H-Index - 179

eISSN - 1365-2133

pISSN - 0007-0963

DOI - 10.1111/bjd.16016

Subject(s) - pirfenidone , medicine , idiopathic pulmonary fibrosis , rash , adverse effect , dermatology , pulmonary fibrosis , fibrosis , disease , interstitial lung disease , lung , gastroenterology

The oral antifibrotic agent, pirfenidone (PFD), 5-methyl-l-phenyl-[1H]-pyridine, is used to treat idiopathic pulmonary fibrosis (IPF), a chronic and fatal lung disease. In trials, PFD reduces disease progression and decreases mortality. The most common side events of PFD are skin manifestations (25%), described as a photosensitivity or rash, but they are not well characterised (1) . This article is protected by copyright. All rights reserved.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research